SCHEMBL18260214

SCHEMBL18260214

OC/C=C/c1ccccc1C#Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ APP P05067 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ LMNA P02545 1/20 0.38
▸ FFAR1 O14842 11/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18260217 1.00 ALDH1A1 (0.43) ALDH1A1MAPTNPC1KDM4EMEN1
SCHEMBL18260224 0.87 TSHR (0.34) ALDH1A1MAPTNPC1KDM4EMEN1
SCHEMBL18260205 0.87 CA12 (0.43) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL18260203 0.87 CA12 (0.43) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL18260227 0.87 TSHR (0.34) ALDH1A1MAPTNPC1KDM4EMEN1
SCHEMBL18260188 0.83 GRM5 (0.46) PTPN1
SCHEMBL18260186 0.83 GRM5 (0.46) PTPN1
SCHEMBL18260249 0.83 ALDH1A1 (0.43) ALDH1A1MAPTNPC1KDM4EMEN1
SCHEMBL30741620 0.83 NPC1 (0.43) ALDH1A1MAPTNPC1KDM4EMEN1
SCHEMBL18260250 0.83 ALDH1A1 (0.43) ALDH1A1MAPTNPC1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708351-B2 Alkenes as alkyne equivalents in radical cascades terminated by fragmentations The Florida State University Research Foundation, Inc. (US) 2017-07-18 — — US disclosed
US-9708351-B2 Alkenes as alkyne equivalents in radical cascades terminated by fragmentations The Florida State University Research Foundation, Inc. (US) 2017-07-18 — — US disclosed
US-9708351-B2 Alkenes as alkyne equivalents in radical cascades terminated by fragmentations The Florida State University Research Foundation, Inc. (US) 2017-07-18 — — US disclosed
US-20160347778-A1 ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS The Florida State University Research Foundation, Inc. 2016-12-01 — — US disclosed
US-20160347778-A1 ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS The Florida State University Research Foundation, Inc. 2016-12-01 — — US disclosed
US-20160347778-A1 ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS The Florida State University Research Foundation, Inc. 2016-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347778-A1 ALKENES AS ALKYNE EQUIVALENTS IN RADICAL CASCADES TERMINATED BY FRAGMENTATIONS AOC3, OR51E2, AOC2 ALDH1A1 913/4885MAPT 4829/4885NPC1 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback